Baxter’s BioScience business applies a unique combination of expertise in medical devices, pharmaceuticals, and biotechnology to create products that improve patient care worldwide.
Baxter is investigating uses within its immunoglobulin portfolio in neurology and immunology, for disorders such as Alzheimer’s disease and multifocal motor neuropathy (MMN).
Baxter’s BioScience business, in conjunction with Halozyme Therapeutics, is investigating developing new delivery technology for subcutaneous administration of IVIG.
Baxter is a fully integrated business that fully complies with regulatory requirements to ensure product safety, efficacy, and quality. This helps assure high quality products from the plasma donors to patients who benefit from our therapies.
The Baxter Global Pathogen Safety Group is an established leader regarding the safety of plasma-derived therapeutics. The group is dedicated and focused on reducing the risk to Baxter products from current and emerging pathogens.
Baxter has a cutting edge biologics manufacturing expertise in plasma fractionation, recombinant protein production, and proprietary Vero cell vaccine production technology. Baxter’s plasma fractionation facilities strive to increase efficiency and support greater product yields, to ensure that more patients have access to its therapies. The company’s experience in plasma fractionation has also resulted in the development of reliable and innovative therapies for the treatment of various chronic conditions.
Baxter BioScience Grants Program
For more information on subcutaneous injection, please click here to view the video.
